Provided by Tiger Trade Technology Pte. Ltd.

Pharvaris N.V.

37.31
+1.042.87%
Post-market: 36.76-0.5500-1.47%19:30 EDT
Volume:691.82K
Turnover:25.78M
Market Cap:2.61B
PE:-12.23
High:38.13
Open:36.27
Low:35.70
Close:36.27
52wk High:38.13
52wk Low:20.65
Shares:69.86M
Float Shares:43.70M
Volume Ratio:1.03
T/O Rate:1.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0508
EPS(LYR):-3.4871
ROE:-70.46%
ROA:-42.32%
PB:7.43
PE(LYR):-10.70

Loading ...

Pharvaris' Deucrictibant Could Be a Game Changer Pending Phase III Results, RBC Says

MT Newswires Live
·
Apr 06

Pharvaris Moves Closer To New Preventive Treatment For Rare Swelling Disorder

Benzinga_recent_news
·
Apr 06

Pharvaris NV reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Apr 06

RBC Trims Price Target on Pharvaris to $51 From $52, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Apr 06

Does CHAPTER-3 Enrollment Milestone and Pipeline Progress Change The Bull Case For Pharvaris (PHVS)?

Simply Wall St.
·
Apr 05

Pharvaris NV expected to post a loss of 70 cents a share - Earnings Preview

Reuters
·
Apr 03

Top Premarket Decliners

MT Newswires Live
·
Apr 02

Pharvaris Posts 2025 Results as Deucrictibant Nears NDA Filing and Key Phase 3 Data

TIPRANKS
·
Apr 02

Pharvaris Q4 EPS $(0.84) Misses $(0.69) Estimate

Benzinga Earnings
·
Apr 02

Earnings Flash (PHVS) Pharvaris Posts Q4 Loss 0.72 Euro a Share

MT Newswires Live
·
Apr 02

Pharvaris FY25 loss widens to €176 million; Q4 loss climbs to €46.7 million

Reuters
·
Apr 02

Pharvaris Nv - FY2025 Loss €176 Mln; Basic and Diluted Loss per Share €2.97

THOMSON REUTERS
·
Apr 02

Press Release: Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Dow Jones
·
Apr 02

Assessing Pharvaris (PHVS) Valuation After Recent Share Price Pullback And Strong Longer Term Returns

Simply Wall St.
·
Mar 29

BioCryst Shares Remain Undervalued, RBC Says

MT Newswires Live
·
Mar 25

Is It Too Late To Consider Pharvaris (PHVS) After A 3.5x Three Year Surge?

Simply Wall St.
·
Mar 23

Pharvaris announces publications of efficacy, safety evidence on deucrictibant

TIPRANKS
·
Mar 20

Pharvaris reports Phase 2 CHAPTER-1 and RAPIDe-1 trial results for oral deucrictibant in hereditary angioedema

Reuters
·
Mar 20

Pharvaris NV director Robert Glassman files initial beneficial ownership statement

Reuters
·
Mar 19

Pharvaris NV Chief Early Development Anne Lesage files initial beneficial ownership statement

Reuters
·
Mar 19